Whitepaper

Whitepaper: Navigating nitrosamine impurity testing

Nitrosamine impurities have become a concern in the bio/pharmaceutical industries, due to their carcinogenic properties and presence in medications.

Nitrosamine impurities have become a concern in the bio/pharmaceutical industries, due to their carcinogenic properties and presence in medications. In response to this issue, we have developed a range of services to help identify and mitigate nitrosamine impurities in drug products. In a recent webinar addressing the bio/pharmaceutical sectors, SGS experts discussed identifying and managing nitrosamine impurities in bio/pharmaceutical products.